| Drug Name |
Clozapine |
| Drug ID |
BADD_D00511 |
| Description |
A tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. |
| Indications and Usage |
For use in patients with treatment-resistant schizophrenia. |
| Marketing Status |
approved |
| ATC Code |
N05AH02 |
| DrugBank ID |
DB00363
|
| KEGG ID |
D00283
|
| MeSH ID |
D003024
|
| PubChem ID |
135398737
|
| TTD Drug ID |
D0Z1RV
|
| NDC Product Code |
73377-150; 51079-288; 51079-749; 51407-085; 63629-2359; 0378-3813; 65862-846; 63552-062; 64374-004; 76072-1010; 16729-142; 57664-345; 0378-0973; 53296-0033; 0093-5416; 51079-921; 51079-922; 57664-211; 65862-845; 69809-0127; 55154-3568; 0378-0825; 0378-0860; 12828-0072; 51407-086; 63629-2360; 69809-0126; 67835-0028; 51862-900; 57664-241; 69809-0135; 70518-3391; 0093-5376; 0093-5417; 51862-902; 60687-404; 60687-415; 63629-2362; 0378-3815; 0904-7088; 65015-706; 0093-5419; 51862-901; 60687-426; 0378-0972; 65862-844; 70518-3357; 65862-847; 0904-7089; 63552-063; 16729-141; 0093-5377; 52817-601; 57664-347; 60687-548; 63629-2361; 69809-0130; 0904-7087; 71554-025; 51862-903 |
| UNII |
J60AR2IKIC
|
| Synonyms |
Clozapine | Clozaril | Leponex |
